following a full submission assessed under the end of life and orphan medicine process:
atezolizumab (Tecentriq®) is accepted for restricted use within NHS Scotland
Indication under review: As monotherapy for the treatment of adult patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.
SMC restriction: treatment with atezolizumab is subject to a two-year clinical stopping rule.
Atezolizumab, compared with a standard taxane monotherapy, significantly improved overall survival in adults with advanced NSCLC who had progressed after platinum-based chemotherapy.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of atezolizumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice373KB (PDF)
- Medicine name:
- atezolizumab (Tecentriq) for NSCLC
- SMC ID:
- Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving Tecentriq.
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published:
- 09 July 2018